Halozyme Therapeutics (HALO) Income towards Parent Company (2010 - 2026)

Halozyme Therapeutics (HALO) has reported Income towards Parent Company for 17 consecutive years, with $150.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Income towards Parent Company rose 27.06% year-over-year to $150.0 million; the TTM figure through Mar 2026 stood at $348.9 million (down 28.12% YoY), while the FY2025 annual figure was $316.9 million, down 28.64% from the prior year.
• Income towards Parent Company grew to $150.0 million in Q1 2026 per HALO's latest filing, from -$141.6 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $175.3 million in Q3 2025 and bottomed at -$141.6 million in Q4 2025.
• Historically, Income towards Parent Company has averaged $82.0 million across 5 years, with a median of $81.8 million in 2023.
• Annual changes were most pronounced in 2023 — Income towards Parent Company surged 229.53% — and 2025, when it plunged 203.34%.
• Halozyme Therapeutics' Income towards Parent Company stood at $57.7 million in 2022, then soared by 47.98% to $85.4 million in 2023, then soared by 60.46% to $137.0 million in 2024, then slumped by 203.34% to -$141.6 million in 2025, then surged by 205.97% to $150.0 million in 2026.
• Business Quant data shows HALO's Income towards Parent Company at $150.0 million in Q1 2026, -$141.6 million in Q4 2025, and $175.3 million in Q3 2025.